Quantum Blue TDM - BÜHLMANN Laboratories AG

Therapeutic Drug Monitoring (TDM)

Infliximab and adalimumab are the most commonly used biologic drugs that target TNF-alpha in a range of different chronic inflammatory diseases such as Inflammatory Bowel Disease (IBD) or Rheumatoid Arthritis (RA). Therapeutic Drug Monitoring (TDM) encompasses measuring drug levels in patient’s blood and the occurrence of antibodies that block the drug (anti-drug antibodies or ADA). With the Quantum Blue^® TDM assays, BÜHLMANN offers a menu of rapid tests for fast and reliable determination of biologic trough levels and anti-drug antibodies. The time to result of 15 minutes allows for quick decision making and optimization of patient’s treatment.

Figure 1: Treatment algorithm adapted from Mitrev et al. 2017, Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases.

Product Information

Test	Quantum Blue^® Infliximab	Quantum Blue^® Anti-Infliximab	Quantum Blue^® Adalimumab	Quantum Blue^® Anti-Adalimumab
Order Code	LF-TLIF25/LF-TLIF10	LF-ADIF25/LF-ADIF10	LF-TLAD25/LF-TLAD10	LF-ADAD25/LF-ADAD10
Time to Result	15 min	15 min	15 min	15 min
Sample Type	serum	serum	serum	serum
Standard Range	0.4-20 µg/ml (180 µg/ml with dilution)	Drug sensitive qualitative assay	1.3-35 µg/ml (500 µg/ml with dilution)	Drug sensitive qualitative assay
Reader Compatibility	Quantum Blue^® Reader 2^nd Generation / Quantum Blue^® Reader 3^rd Generation	Quantum Blue^® Reader 2^nd Generation / Quantum Blue^® Reader 3^rd Generation	Quantum Blue^® Reader 2^nd Generation / Quantum Blue^® Reader 3^rd Generation	Quantum Blue^® Reader 2^nd Generation / Quantum Blue^® Reader 3^rd Generation